Antiemetic prophylaxis multiplies, and rescue changes class

Why it matters

Postoperative nausea and vomiting is the PACU problem residents believe they understand best, and the one they most often reason about wrongly. The wrong reasoning is additive: two antiemetics are twice as good as one, and a patient who vomits despite prophylaxis needs more of the same. The trial that tested prophylaxis factorially says the effects are independent and multiply, that the absolute benefit depends on where the patient started, and that prophylaxis is rarely warranted in low-risk patients apfel-2004. The current guideline says rescue must change class gan-2026.

The consequence of getting this wrong runs in both directions. A low-risk patient is given three drugs for a small absolute gain, and a high-risk patient who vomits in the PACU is given a second dose of the drug that already failed.

Mechanism

Each antiemetic class blocks a different input to the vomiting reflex: serotonin at 5-HT3 receptors, dopamine at D2 receptors, corticosteroid effects that are still incompletely characterised, and the removal of emetogenic anaesthetic agents themselves. Because the inputs are distinct, blocking one does not change the fraction of remaining risk that another can remove. That is what independence means pharmacologically, and it is why the arithmetic is multiplicative on the relative-risk scale: each intervention removes its own fraction of whatever risk is left. It is also why a rescue drug must act on an input the prophylaxis did not touch. Repeating a class that has already failed to control the reflex adds little except its side effects.

Evidence

Apfel 1999 identified four predictors, female sex, history of motion sickness or PONV, non-smoking status and postoperative opioids, and cross-validated the score between two centres apfel-1999. With 0, 1, 2, 3 or 4 factors the abstract gives risks of 10%, 21%, 39%, 61% and 79%; the results text gives 78% at four factors, so the paper is internally inconsistent at that step, and the discriminating power was an area under the curve of about 0.75 apfel-1999.

The IMPACT trial randomised 4123 of 5199 enrolled patients across 64 combinations of six interventions apfel-2004. Ondansetron, dexamethasone and droperidol each reduced relative risk by about 26%, propofol by 19%, and avoiding nitrous oxide by 12% apfel-2004. The authors’ own words on combining them: all the interventions acted independently of one another and independently of the patients’ baseline risk, so the relative risks of the combined interventions could be estimated by multiplying the relative risks of each apfel-2004. Absolute risk reduction, they add, is a critical function of baseline risk, and prophylaxis is rarely warranted in low-risk patients apfel-2004.

The Fifth Consensus Guidelines, in print in 2026, supersede the Fourth gan-2026 gan-2020. They retain the Apfel score but round the ladder to approximately 10%, 20%, 40%, 60% and 80%, banded as 0 factors low, 1 to 2 medium, and 3 or more high gan-2026. Guideline 4, verbatim: patients should receive rescue treatment from a different pharmacological class to the prophylactic agents administered gan-2026. If more than 6 h has elapsed, a second dose of a 5-HT3 antagonist or a butyrophenone may be considered if no alternatives exist; long-acting agents, aprepitant, fosaprepitant and palonosetron, should not be re-dosed in the PACU; transdermal scopolamine is not an effective rescue agent because of its slow onset; and amisulpride 10 mg is the FDA-recommended rescue dose, graded A3 gan-2026.

The Fifth guideline also grades as A1 that low-dose gabapentinoids, below 300 mg of pregabalin or 900 mg of gabapentin per day, reduce PONV risk despite no significant analgesic effect, and as A1 that opioid-free anaesthesia reduces PONV compared with opioid-based anaesthesia gan-2026.

What this does not show

The multiplicative rule is a statement about relative risk. It does not mean every patient benefits equally: the same three interventions remove a large absolute risk from a patient at 80% and a small one from a patient at 10%, which is the whole reason the trial’s conclusion discourages prophylaxis in low-risk patients apfel-2004. A page that quotes the relative risk reductions without the baseline is quoting half the result.

The Apfel score is a population instrument with an area under the curve of about 0.75 apfel-1999. It sorts patients into bands; it does not predict an individual. The two versions of its ladder, the 1999 values and the guideline’s rounded ones, disagree by one or two points at every step, and this page uses the guideline’s rounded values because they are current, they are what the guideline algorithm uses, and rounded values do not invite spurious precision gan-2026.

The IMPACT per-intervention incidence table broken down by number of antiemetics has not been extracted from the held paper; only the summary relative risk reductions appear here apfel-2004. The erratum to the Fourth guideline has not been read, so no dose or table from the 2020 document is quoted on this page gan-2020-erratum.

Drug-specific cautions the director’s content list expects here, dexamethasone timing, the droperidol QT warning, ondansetron’s QT effect and its limited action on the vestibular component, and scopolamine’s anticholinergic burden in the elderly, are not in the held sources beyond what is quoted above. They are placeholders: [NUMBER NEEDED: dexamethasone timing at induction versus emergence] [NUMBER NEEDED: droperidol QT boxed warning wording and dose] [NUMBER NEEDED: ondansetron QT effect and vestibular limitation] [NUMBER NEEDED: scopolamine onset lag and anticholinergic burden in the elderly].

At the bedside

Count the factors before the patient leaves the operating room and write the band down, using the guideline’s rounded ladder and its three bands gan-2026. Match the number of prophylactic interventions to the band, remembering that the absolute benefit is what you are buying and the baseline risk is what sets its price apfel-2004.

When a patient vomits in the PACU, the first question is which classes were already given. The rescue must come from a class the patient has not received gan-2026. Do not re-dose a long-acting agent, do not reach for a scopolamine patch as rescue, and reserve a second dose of the prophylactic class for the situation the guideline describes, more than 6 h elapsed and nothing else available gan-2026.

[PRACTICE VARIES: the specific rescue agents stocked and the order in which they are used differ between institutions; the class-change rule does not.]

Check yourself

Four items. Every option carries an explanation. Progress is not saved.